CSF3 and neutropenia: Aagaard et al. [57] subsequently expanded on their work with the CSRFENCE score for chemotherapy cycles 2–6 of a patient’s treatment, and added chemotherapy selection, cycle number, previous FN or neutropenia, and G-CSF use as variables.